Multiple sclerosis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Template:Multiple sclerosis}}
{{Template:Multiple sclerosis}}
{{CMG}}; {{AE}}; [[User:Irfan Dotani|Irfan Dotani]]
{{CMG}}; {{AE}} {{Fs}}
 
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.


==Overview==
==Overview==
Effective measures for the [[primary prevention]] of multiple sclerosis include: [[Vitamin D]] supplement, [[smoking]] cessation, and early exposure to [[infection]].
Effective measures for the [[primary prevention]] of multiple sclerosis include: [[Vitamin D]] supplement, [[smoking]] cessation, and early exposure to [[infection]]<nowiki/>s.


==Primary Prevention==
==Primary Prevention==
Effective measures for the [[primary prevention]] of multiple sclerosis include:
Effective measures for the [[primary prevention]] of multiple sclerosis include:
* [[Vitamin D]] supplement: There is some evidence demonstrating that 1000 to 4000 IU [[vitamin D]] supplement daily can reduce the [[incidence]] of multiple sclerosis.<ref name="pmid15671234">{{cite journal |vauthors=Hollis BW |title=Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D |journal=J. Nutr. |volume=135 |issue=2 |pages=317–22 |date=February 2005 |pmid=15671234 |doi= |url=}}</ref><ref name="pmid15776217">{{cite journal |vauthors=Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R |title=Estimates of optimal vitamin D status |journal=Osteoporos Int |volume=16 |issue=7 |pages=713–6 |date=July 2005 |pmid=15776217 |doi=10.1007/s00198-005-1867-7 |url=}}</ref><ref name="pmid10232622">{{cite journal |vauthors=Vieth R |title=Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety |journal=Am. J. Clin. Nutr. |volume=69 |issue=5 |pages=842–56 |date=May 1999 |pmid=10232622 |doi= |url=}}</ref>


==== Vitamin D supplement ====
* Smoking cessation: [[Smoking]] cessation proved to be beneficial in reducing the [[incidence]] of MS disease.<ref name="pmid11427406">{{cite journal |vauthors=Hernán MA, Olek MJ, Ascherio A |title=Cigarette smoking and incidence of multiple sclerosis |journal=Am. J. Epidemiol. |volume=154 |issue=1 |pages=69–74 |date=July 2001 |pmid=11427406 |doi= |url=}}</ref>
There is some evidence demonstrating that 1000 to 4000 IU [[vitamin D]] supplement daily can reduce the incidence of multiple sclerosis.<ref name="pmid15671234">{{cite journal |vauthors=Hollis BW |title=Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D |journal=J. Nutr. |volume=135 |issue=2 |pages=317–22 |date=February 2005 |pmid=15671234 |doi= |url=}}</ref><ref name="pmid15776217">{{cite journal |vauthors=Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R |title=Estimates of optimal vitamin D status |journal=Osteoporos Int |volume=16 |issue=7 |pages=713–6 |date=July 2005 |pmid=15776217 |doi=10.1007/s00198-005-1867-7 |url=}}</ref><ref name="pmid10232622">{{cite journal |vauthors=Vieth R |title=Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety |journal=Am. J. Clin. Nutr. |volume=69 |issue=5 |pages=842–56 |date=May 1999 |pmid=10232622 |doi= |url=}}</ref>
 
==== Smoking cessation ====
[[Smoking]] cessation proved to be beneficial in reducing the incidence of MS disease.<ref name="pmid11427406">{{cite journal |vauthors=Hernán MA, Olek MJ, Ascherio A |title=Cigarette smoking and incidence of multiple sclerosis |journal=Am. J. Epidemiol. |volume=154 |issue=1 |pages=69–74 |date=July 2001 |pmid=11427406 |doi= |url=}}</ref>
 
==== Early exposure to infections ====
[[EBV infection]] in childhood is not a severe disease, but in adults, it can presents as [[infectious mononucleosis]]. The similarity between the prevalence of [[infectious mononucleosis]] and [[MS]] point out that infection with this [[EBV|virus]] in childhood can reduce the risk of [[MS]] in comparison with adulthood infection.<ref name="pmid6118702">{{cite journal |vauthors=Warner HB, Carp RI |title=Multiple sclerosis and Epstein-Barr virus |journal=Lancet |volume=2 |issue=8258 |pages=1290 |date=December 1981 |pmid=6118702 |doi= |url=}}</ref><ref name="pmid12239261">{{cite journal |vauthors=Bach JF |title=The effect of infections on susceptibility to autoimmune and allergic diseases |journal=N. Engl. J. Med. |volume=347 |issue=12 |pages=911–20 |date=September 2002 |pmid=12239261 |doi=10.1056/NEJMra020100 |url=}}</ref>


* Early exposure to infections: [[EBV infection]] in childhood is not a severe disease, but in adults, it can presents as [[infectious mononucleosis]]. The similarity between the [[prevalence]] of [[infectious mononucleosis]] and [[MS]] point out that infection with this [[EBV|virus]] in childhood can reduce the risk of [[MS]] in comparison with adulthood infection.<ref name="pmid6118702">{{cite journal |vauthors=Warner HB, Carp RI |title=Multiple sclerosis and Epstein-Barr virus |journal=Lancet |volume=2 |issue=8258 |pages=1290 |date=December 1981 |pmid=6118702 |doi= |url=}}</ref><ref name="pmid12239261">{{cite journal |vauthors=Bach JF |title=The effect of infections on susceptibility to autoimmune and allergic diseases |journal=N. Engl. J. Med. |volume=347 |issue=12 |pages=911–20 |date=September 2002 |pmid=12239261 |doi=10.1056/NEJMra020100 |url=}}</ref>
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}


[[Category:Primary care]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Orthopedics]]
[[Category:Orthopedics]]
[[Category:Rheumatology]]
[[Category:Rheumatology]]
{{WH}}
{{WS}}

Latest revision as of 22:48, 29 July 2020

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis primary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis primary prevention

CDC on Multiple sclerosis primary prevention

Multiple sclerosis primary prevention in the news

Blogs on Multiple sclerosis primary prevention

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Effective measures for the primary prevention of multiple sclerosis include: Vitamin D supplement, smoking cessation, and early exposure to infections.

Primary Prevention

Effective measures for the primary prevention of multiple sclerosis include:

  • Smoking cessation: Smoking cessation proved to be beneficial in reducing the incidence of MS disease.[4]

References

  1. Hollis BW (February 2005). "Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D". J. Nutr. 135 (2): 317–22. PMID 15671234.
  2. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (July 2005). "Estimates of optimal vitamin D status". Osteoporos Int. 16 (7): 713–6. doi:10.1007/s00198-005-1867-7. PMID 15776217.
  3. Vieth R (May 1999). "Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety". Am. J. Clin. Nutr. 69 (5): 842–56. PMID 10232622.
  4. Hernán MA, Olek MJ, Ascherio A (July 2001). "Cigarette smoking and incidence of multiple sclerosis". Am. J. Epidemiol. 154 (1): 69–74. PMID 11427406.
  5. Warner HB, Carp RI (December 1981). "Multiple sclerosis and Epstein-Barr virus". Lancet. 2 (8258): 1290. PMID 6118702.
  6. Bach JF (September 2002). "The effect of infections on susceptibility to autoimmune and allergic diseases". N. Engl. J. Med. 347 (12): 911–20. doi:10.1056/NEJMra020100. PMID 12239261.

Template:WH Template:WS